Prognostic significance of elevated creatine kinase MB after coronary bypass surgery and after an acute coronary syndrome: Results from the GUARDIAN trial

Journal of Thoracic and Cardiovascular Surgery

Volumn 126, Issue 3, 2003, Pages 807-813

  Gavard, Jeffrey A ^a   Chaitman, Bernard R ^a   Sakai, Shunta ^a   Stocke, Karen ^a   Danchin, Nicolas ^b   Erhardt, Leif ^c   Gallo, Richard ^d   Chi, Eric ^e   Jessel, Andreas ^e   Théroux, Pierre ^d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d MONTREAL HEART INSTITUTE   (Canada)

^e SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARIPORIDE; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

EID: 0141519212     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5223(03)00735-9     Document Type: Article

References (25)

1. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241-51.
2. Tardiff BE, Califf RM, Tcheng JE, et al, for the IMPACT-II Investigators. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention, Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis II. J Am Coll Cardiol. 1999;33:88-96.
3. Kong TQ, Davidson CJ, Myers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA. 1997;277:461-6.
4. Abdelmeguid AE, Topol EJ. The myth of the myocardial " infarctlet" during percutaneous coronary revascularization procedures. Circulation. 1996;94:3369-75.
5. Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol. 2002;40:1961-7.
6. Klatte K, Chaitman BR, Theroux P, et al. Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release. Results from the GUARDIAN trial. J Am Coll Cardiol. 2001;38:1070-7.
7. Costa MA, Carere RG, Lichtenstein SV, et al. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the Arterial Revascularization Therapies Study (ARTS). Circulation. 2001;104:2689-93.
8. Steuer J, Horte LG, Lindahl B, Stahle E. Impact of perioperative myocardial injury on early and long-term outcome after coronary artery bypass grafting. Eur Heart J. 2002;23:1219-27.
9. Fremes SE, Tamariz MG, Abramov D, et al. Late results of the Warm Heart Trial: the influence of nonfatal cardiac events on late survival. Circulation. 2000;102:III339-45.
10. Theroux P, Chaitman BR, Erhardt L, et al. Design of a trial evaluating myocardial cell protection with Cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger. The Guard During Ischemia Against Necrosis (GUARDIAN) trial. Curr Controlled Trials Cardiovasc Med. 2000;1:59-67.
11. Theroux P, Chaitman BR, Danchin N, et al, for the Guard During Ischemia Against Necrosis (GUARDIAN) Investigators. Inhibition of the sodium-hydrogen exchanger with Cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial. Circulation. 2000;102:3032-8.
12. Boyce SW, Bartels C, Bolli R, et al, on behalf of the GUARDIAN Study Investigators. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG Surgery Cohort of the GUARDIAN Study. J Thorac Cardiovasc Surg. 2003;126:420-7.
13. Armitage P, Berry G. Statistical methods in medical research. Cambridge (MA): Blackwell Scientific Publications; 1994;397-9, 453-60.
14. Cutler SJ, Ederer F. Maximum utilization of the lifetable method in analyzing survival. J Chronic Dis. 1958;8:699-712.
15. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 1980.
16. Labinaz M, Kilaru R, Pieper K, et al, for the PURSUIT Investigators. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Circulation. 2002;105:322-7.
17. Cannon CP, Thompson B, McCabe CH, et al. Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III trials. Am J Cardiol. 1995;75:977-81.
18. Ryan TJ, Antman EM, Brooks NH, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Available at www. acc.org.
19. Ellis SG, Schneider JP, Topol EJ. Comparison of long-term survival following non-Q-wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated. Am J Cardiol. 2002;89:751-3.
20. Sharma SK, Kini A, Marmur JD, Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival. Circulation. 2000;102:166-72.
21. Alyanakian MA, Deboux M, Chatel D, et al. Cardiac troponin I in diagnosis of perioperative myocardial infarction after cardiac surgery. J Cardiothorac Vasc Anesth. 1998;12:288-94.
22. Astorri E, Fiorina P, Grattagliano C, et al. Cardiac troponin T to evaluate myocardial protection via intermittent cold blood or continuous warm blood cardioplegia in coronary artery bypass grafting. J Cardiovasc Surg (Torino). 1998;39:797-802.
23. Carrier M, Pellerin M, Perrault LP, Solymoss BC, Pelletier LC. Troponin levels in patients with myocardial infarction after coronary artery bypass grafting. Ann Thorac Surg. 2000;69:435-40.
24. Newby LK, Alpert JS, Ohman EM, Thygesen K, Califf RM. Diagnosis of myocardial infarction. Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. Am Heart J. 2002;144:957-80.
25. Apple FS, Wu AHB, Jaffe AS. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J. 2002;144:981-6.